Obtaining long-term disease specific costs of care

Application to medicare enrollees diagnosed with colorectal cancer

Martin L. Brown, Gerald F. Riley, Arnold L. Potosky, Ruth Etzioni

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

OBJECTIVES. This study develops estimates of long-term, cancer-related treatment cost using a modeling approach and data from the SEER-Medicare linked database. The method is demonstrated for colorectal cancer. METHODS. Data on Medicare payments were obtained for colorectal cancer patients for the years 1990 to 1994 from the SEER-Medicare linked database. Claims payment data for control subjects were obtained for Medicare enrollees without cancer residing in the same areas as patients. Estimates of long-term cost (≤25 years following the date of diagnosis) were obtained by combining treatment/phasespecific cost estimates with estimates of longterm survival from SEER. Treatment phases were defined as initial care, terminal care, and continuing care. Cancer-related estimates for each phase were obtained by subtracting costs for control subjects from the observed costs for cancer patients, matching on age group, gender, and registry area. Estimates of long-term cost ≤11 years obtained by this method were compared with 11-year estimates obtained by application of the Kaplan-Meier sample average (KMSA) method. RESULTS. The mean initial-phase cancerrelated cost was approximately $18,000 but was higher among patients with more advanced cancer. The mean continuing-phase cancerrelated cost was $1,500 per year and declined with increasing age, but was higher on an annual basis among persons with later stages of cancer and shorter survival time. The mean terminal-phase cancer-related cost was $15,000 and declined with both age at death and more advanced stage at diagnosis. After the phasespecific estimates were combined, the average long-term cancer-related cost was $33,700 ($31,300 at 3% discount rate) for colon cancer compared with $36,500 ($33,800 at 3% discount rate) for cancer of the rectum. This represented about half of the total long-term cost for Medicare enrollees diagnosed with this disease. Long-term cost was highest for Stage III cancer and lowest for in situ cancer. Eleven-year cancer-related costs estimated by the KMSA method were similar to estimates using the phase-based approach. CONCLUSIONS. This paper demonstrates that valid estimates of cancer-related long-term cost can be obtained from administrative claims data linked to incidence cancer registry data.

Original languageEnglish (US)
Pages (from-to)1249-1259
Number of pages11
JournalMedical care
Volume37
Issue number12
DOIs
StatePublished - Dec 1 1999
Externally publishedYes

Fingerprint

Cost of Illness
Medicare
Colorectal Neoplasms
Costs and Cost Analysis
Neoplasms
Health Care Costs
Registries
Databases
Terminal Care
Survival
Cost Control
Rectal Neoplasms
Colonic Neoplasms

Keywords

  • Cancer
  • Colon
  • Costs
  • Methods
  • Rectum

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Obtaining long-term disease specific costs of care : Application to medicare enrollees diagnosed with colorectal cancer. / Brown, Martin L.; Riley, Gerald F.; Potosky, Arnold L.; Etzioni, Ruth.

In: Medical care, Vol. 37, No. 12, 01.12.1999, p. 1249-1259.

Research output: Contribution to journalArticle

Brown, Martin L. ; Riley, Gerald F. ; Potosky, Arnold L. ; Etzioni, Ruth. / Obtaining long-term disease specific costs of care : Application to medicare enrollees diagnosed with colorectal cancer. In: Medical care. 1999 ; Vol. 37, No. 12. pp. 1249-1259.
@article{d76000e0e8fd46e8b2ea56b3a0918e7c,
title = "Obtaining long-term disease specific costs of care: Application to medicare enrollees diagnosed with colorectal cancer",
abstract = "OBJECTIVES. This study develops estimates of long-term, cancer-related treatment cost using a modeling approach and data from the SEER-Medicare linked database. The method is demonstrated for colorectal cancer. METHODS. Data on Medicare payments were obtained for colorectal cancer patients for the years 1990 to 1994 from the SEER-Medicare linked database. Claims payment data for control subjects were obtained for Medicare enrollees without cancer residing in the same areas as patients. Estimates of long-term cost (≤25 years following the date of diagnosis) were obtained by combining treatment/phasespecific cost estimates with estimates of longterm survival from SEER. Treatment phases were defined as initial care, terminal care, and continuing care. Cancer-related estimates for each phase were obtained by subtracting costs for control subjects from the observed costs for cancer patients, matching on age group, gender, and registry area. Estimates of long-term cost ≤11 years obtained by this method were compared with 11-year estimates obtained by application of the Kaplan-Meier sample average (KMSA) method. RESULTS. The mean initial-phase cancerrelated cost was approximately $18,000 but was higher among patients with more advanced cancer. The mean continuing-phase cancerrelated cost was $1,500 per year and declined with increasing age, but was higher on an annual basis among persons with later stages of cancer and shorter survival time. The mean terminal-phase cancer-related cost was $15,000 and declined with both age at death and more advanced stage at diagnosis. After the phasespecific estimates were combined, the average long-term cancer-related cost was $33,700 ($31,300 at 3{\%} discount rate) for colon cancer compared with $36,500 ($33,800 at 3{\%} discount rate) for cancer of the rectum. This represented about half of the total long-term cost for Medicare enrollees diagnosed with this disease. Long-term cost was highest for Stage III cancer and lowest for in situ cancer. Eleven-year cancer-related costs estimated by the KMSA method were similar to estimates using the phase-based approach. CONCLUSIONS. This paper demonstrates that valid estimates of cancer-related long-term cost can be obtained from administrative claims data linked to incidence cancer registry data.",
keywords = "Cancer, Colon, Costs, Methods, Rectum",
author = "Brown, {Martin L.} and Riley, {Gerald F.} and Potosky, {Arnold L.} and Ruth Etzioni",
year = "1999",
month = "12",
day = "1",
doi = "10.1097/00005650-199912000-00008",
language = "English (US)",
volume = "37",
pages = "1249--1259",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Obtaining long-term disease specific costs of care

T2 - Application to medicare enrollees diagnosed with colorectal cancer

AU - Brown, Martin L.

AU - Riley, Gerald F.

AU - Potosky, Arnold L.

AU - Etzioni, Ruth

PY - 1999/12/1

Y1 - 1999/12/1

N2 - OBJECTIVES. This study develops estimates of long-term, cancer-related treatment cost using a modeling approach and data from the SEER-Medicare linked database. The method is demonstrated for colorectal cancer. METHODS. Data on Medicare payments were obtained for colorectal cancer patients for the years 1990 to 1994 from the SEER-Medicare linked database. Claims payment data for control subjects were obtained for Medicare enrollees without cancer residing in the same areas as patients. Estimates of long-term cost (≤25 years following the date of diagnosis) were obtained by combining treatment/phasespecific cost estimates with estimates of longterm survival from SEER. Treatment phases were defined as initial care, terminal care, and continuing care. Cancer-related estimates for each phase were obtained by subtracting costs for control subjects from the observed costs for cancer patients, matching on age group, gender, and registry area. Estimates of long-term cost ≤11 years obtained by this method were compared with 11-year estimates obtained by application of the Kaplan-Meier sample average (KMSA) method. RESULTS. The mean initial-phase cancerrelated cost was approximately $18,000 but was higher among patients with more advanced cancer. The mean continuing-phase cancerrelated cost was $1,500 per year and declined with increasing age, but was higher on an annual basis among persons with later stages of cancer and shorter survival time. The mean terminal-phase cancer-related cost was $15,000 and declined with both age at death and more advanced stage at diagnosis. After the phasespecific estimates were combined, the average long-term cancer-related cost was $33,700 ($31,300 at 3% discount rate) for colon cancer compared with $36,500 ($33,800 at 3% discount rate) for cancer of the rectum. This represented about half of the total long-term cost for Medicare enrollees diagnosed with this disease. Long-term cost was highest for Stage III cancer and lowest for in situ cancer. Eleven-year cancer-related costs estimated by the KMSA method were similar to estimates using the phase-based approach. CONCLUSIONS. This paper demonstrates that valid estimates of cancer-related long-term cost can be obtained from administrative claims data linked to incidence cancer registry data.

AB - OBJECTIVES. This study develops estimates of long-term, cancer-related treatment cost using a modeling approach and data from the SEER-Medicare linked database. The method is demonstrated for colorectal cancer. METHODS. Data on Medicare payments were obtained for colorectal cancer patients for the years 1990 to 1994 from the SEER-Medicare linked database. Claims payment data for control subjects were obtained for Medicare enrollees without cancer residing in the same areas as patients. Estimates of long-term cost (≤25 years following the date of diagnosis) were obtained by combining treatment/phasespecific cost estimates with estimates of longterm survival from SEER. Treatment phases were defined as initial care, terminal care, and continuing care. Cancer-related estimates for each phase were obtained by subtracting costs for control subjects from the observed costs for cancer patients, matching on age group, gender, and registry area. Estimates of long-term cost ≤11 years obtained by this method were compared with 11-year estimates obtained by application of the Kaplan-Meier sample average (KMSA) method. RESULTS. The mean initial-phase cancerrelated cost was approximately $18,000 but was higher among patients with more advanced cancer. The mean continuing-phase cancerrelated cost was $1,500 per year and declined with increasing age, but was higher on an annual basis among persons with later stages of cancer and shorter survival time. The mean terminal-phase cancer-related cost was $15,000 and declined with both age at death and more advanced stage at diagnosis. After the phasespecific estimates were combined, the average long-term cancer-related cost was $33,700 ($31,300 at 3% discount rate) for colon cancer compared with $36,500 ($33,800 at 3% discount rate) for cancer of the rectum. This represented about half of the total long-term cost for Medicare enrollees diagnosed with this disease. Long-term cost was highest for Stage III cancer and lowest for in situ cancer. Eleven-year cancer-related costs estimated by the KMSA method were similar to estimates using the phase-based approach. CONCLUSIONS. This paper demonstrates that valid estimates of cancer-related long-term cost can be obtained from administrative claims data linked to incidence cancer registry data.

KW - Cancer

KW - Colon

KW - Costs

KW - Methods

KW - Rectum

UR - http://www.scopus.com/inward/record.url?scp=0033251001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033251001&partnerID=8YFLogxK

U2 - 10.1097/00005650-199912000-00008

DO - 10.1097/00005650-199912000-00008

M3 - Article

VL - 37

SP - 1249

EP - 1259

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 12

ER -